The G501C polymorphism of oxidized LDL receptor gene [OLR-1] is associated with susceptibility and serum C-reactive protein concentration in Chinese essential hypertensives

Clinica Chimica Acta

Volumn 388, Issue 1-2, 2008, Pages 200-203

  Hou, Xu wei ^a   Wang, Li fang ^b   Wang, Ningfu ^a   Pang, Detang ^c   Hui, Bo ^d   Zhou, Yu ling ^e   He, Xiuying ^a  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Department of Interne Medicine   (China)

^d QINGDAO MUNICIPAL HOSPITAL   (China)

^e INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Chinese; Essential hypertension; G501C polymorphism; Oxidized LDL receptor

Indexed keywords

C REACTIVE PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OPEN READING FRAME; OXIDIZED LDL RECEPTOR 1 GENE; PRIORITY JOURNAL; SEX RATIO;

C-REACTIVE PROTEIN; CHINA; CYSTEINE; FEMALE; GENOTYPE; GLYCINE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SCAVENGER RECEPTORS, CLASS E; SERUM;

EID: 37449025817     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.11.016     Document Type: Article

References (28)

1. Taddei S., Virdis A., Ghiadoni L., Sudano I., and Salvetti A. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 38 Suppl 2 (2001) S11-S14
2. Tzemos N., Lim P.O., and MacDonald T.M. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104 5 (2001) 511-514
3. Brunner H., Cockcroft J.R., Deanfield J., Donald A., Ferrannini E., Halcox J., et al. Endothelial function and dysfunction. Part II:Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 23 2 (2005) 233-246
4. Sawamura T., Kume N., Aoyama T., Moriwaki H., Miwa S., Kita T., et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 386 (1997) 73-77
5. Mehta J.L., and Li D.Y. Identification and autoregulation of receptor for Ox-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun 248 (1998) 511-514
6. Honjo M., Nakamura K., Yamashiro K., Kiryu J., Tanihara H., McEvoy L.M., et al. Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci U S A 100 3 (2003) 1274-1279
7. Cilingiroglu M., and Ozer K. The lectin-like oxidized low-density lipoprotein receptor and its role in atherosclerosis. Curr Atheroscler Rep 7 2 (2005) 103-107
8. Li D., and Mehta J.L. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 101 25 (2000) 2889-2895
9. Cominacini L., Rigoni A., Pasini A.F., Garbin U., Davoli A., Campagnola M., et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 276 17 (2001) 13750-13755
10. Puccetti L., Pasqui A.L., Bruni F., Pastorelli M., Ciani F., Palazzuoli A., et al. Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. Int J Cardiol (2006)
11. Ohmori R., Momiyama Y., Nagano M., Taniguchi H., Egashira T., Yonemura A., et al. An oxidized low-density lipoprotein receptor gene variant is inversely associated with the severity of coronary artery disease. Clin Cardiol 27 11 (2004) 641-644
12. Chen Q., Reis S.E., Kammerer C., Craig W.Y., LaPierre S.E., Zimmer E.L., et al. Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. Circulation 107 25 (2003) 3146-3151 Epub 2003 Jun 16
13. Novelli G., Borgiani P., Mango R., Romeo F., and Mehta J.L. OLR1 gene and coronary artery disease/acute myocardial infarction: replication in an independently collected sample. Eur J Hum Genet 14 8 (2006) 894-895
14. Tatsuguchi M., Furutani M., Hinagata J., Tanaka T., Furutani Y., Imamura S., et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun 303 1 (2003) 247-250
15. Mango R., Biocca S., del Vecchio F., Clementi F., Sangiuolo F., Amati F., et al. In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction. Circ Res 97 2 (2005) 152-158
16. Trabetti E., Biscuola M., Cavallari U., Malerba G., Girelli D., Olivieri O., et al. On the association of the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction or coronary artery disease. Eur J Hum Genet 14 1 (2006) 127-130
17. Ohki I., Ishigaki T., Oyama T., Matsunaga S., Xie Q., Ohnishi-Kameyama M., et al. Crystal Structure of Human Lectin-like, Oxidized Low-Density Lipoprotein Receptor 1 Ligand Binding Domain and its Ligand Recognition Mode to OxLDL. Structure 13 5 (2005) 905-917
18. Virdis A., and Schiffrin E.L. Vascular inflammation: a role in vascular disease in hypertension?. Curr Opin Nephrol Hypertens 12 2 (2003) 181-187
19. Li J.J., and Chen J.L. Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses 64 5 (2005) 925-929
20. Savoia C., and Schiffrin E.L. Inflammation in hypertension. Curr Opin Nephrol Hypertens 15 2 (2006) 152-158
21. Brasier A.R., Recinos III A., and Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22 8 (2002) 1257-1266
22. Hermann M., Enseleit F., and Ruschitzka F.T. Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2. Curr Hypertens Rep 7 1 (2005) 52-60
23. Sciarretta S., Ferrucci A., Ciavarella G.M., De Paolis P., Venturelli V., Tocci G., et al. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens 20 7 (2007) 784-791
24. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and 8 risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107 3 (2003) 391-397
25. Thorand B., Lowel H., Schneider A., Kolb H., Meisinger C., Frohlich M., et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 163 1 (2003) 93-99
26. Cottone S., Mule G., Nardi E., Vadala A., Lorito M.C., Guarneri M., et al. C-reactive protein and intercellular adhesion molecule-1 are stronger predictors of oxidant stress than blood pressure in established hypertension. J Hypertens 25 2 (2007) 423-428
27. Sung K.C., Suh J.Y., Kim B.S., Kang J.H., Kim H., Lee M.H., et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 16 6 (2003) 429-433
28. Li L., Roumeliotis N., Sawamura T., and Renier G. C-reactive protein enhances LOX-1 expression In human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 95 9 (2004) 877-888